EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

21 July 2023
EMA/CVMP/IWP/170689/2016
Committee for Veterinary Medicinal Products (CVMP)

# Guideline on requirements for the quality (production and control), safety and efficacy of allergen products for use in horses, dogs and cats

| | |
|---|---|
| Draft agreed by Immunologicals Working Party | October 2018 |
| Adopted by CVMP for release for consultation | 6 December 2018 |
| Start of public consultation | 14 December 2018 |
| End of consultation (deadline for comments) | 31 August 2019 |
| Agreed by Immunologicals Working Party | 25 April 2023 |
| Adopted by CVMP | 13 July 2023 |
| Date for coming into effect | 13 January 2024 |

This guideline will replace the existing Note for Guidance on 'Specific Requirements for the Production and Control of Allergen products (7BIm11a)', adopted prior to September 1994.



| **Keywords** | Allergen products, requirements, cats, dogs, horses |
|---|---|



**Official address** Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
**Address for visits and deliveries** Refer to www.ema.europa.eu/how-to-find-us
**Send us a question** Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union

© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged.

© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged.

# Guideline on requirements for the quality (production and control), safety and efficacy of allergen products for use in horses, dogs and cats

## Table of contents

**Executive summary ... 3**

**1. Introduction (background) ... 3**

**2. Scope ... 4**

**3. Legal basis ... 4**

**4. General concepts ... 5**

4.1. Homologous groups ... 5

4.2. Allergen mixtures ... 6

4.3. Comparability (batch-to batch consistency) ... 6

**5. Quality ... 7**

5.1. Active substance ... 7

5.1.1. General information ... 7

5.1.2. Manufacture ... 7

5.1.3. Control of starting materials ... 8

5.1.4. Characterisation and control of the active substance ... 9

5.1.5. Stability of the active substance ... 11

5.2. Standards and reference materials ... 11

5.3. Manufacturing and control of finished product ... 12

5.3.1. Description and composition of the finished product ... 12

5.3.2. Manufacture ... 12

5.3.3. Control of the finished product ... 13

5.3.4. Container closure system ... 14

5.3.5. Stability of the finished product ... 14

**6. Safety and Efficacy testing ... 15**

6.1. Safety studies with veterinary allergen products for immunotherapy treatment ... 16

6.2. Efficacy studies with veterinary allergen products for immunotherapy treatment ... 17

6.3. Safety and Efficacy studies for in vivo diagnosis with veterinary allergen products ... 18

**Definitions ... 19**

**References ... 21**

**ANNEX I ... 23**

**ANNEX II ... 25**

# Executive summary

This guideline lays down the quality recommendations for allergen products of biological origin, including allergen extracts derived from natural source material and allergens produced through recombinant DNA technology, used for immunotherapy treatment (AIT: Allergen Immunotherapy treatment /SIT: Specific Immunotherapy treatment) or *in vivo* diagnosis of immunoglobulin E (IgE)-mediated allergic diseases in horses, dogs and cats.

In addition, guidance is given for the clinical testing regarding safety and efficacy of allergen products.

# 1. Introduction (background)

Allergic diseases in horses, dogs and cats are gaining great importance in veterinary practice in recent years. Allergies are driven by the hypersensitivity of the immune system to exogenous substances and can affect various target organs. The major allergic diseases of dogs, cats and horses affect the skin (e.g. canine and feline atopic dermatitis, insect-bite hypersensitivity in horses), respiratory tract (e.g. feline asthma, equine recurrent airway obstruction) and intestinal tract (food allergy).

Immunologically, the majority of these allergic diseases are suggested to have a Type I hypersensitivity pathogenesis. Type I (immediate) reactions are defined as vigorous responses of the immune system triggered by the interaction of allergens with specific IgE antibodies leading to the release of inflammatory mediators including histamine, cytokines and lipid mediators.

The diagnosis of an existing allergy is aided by the use of intradermal testing using allergen extracts. If allergen avoidance of the offending allergen is not possible, allergen immunotherapy is a treatment option. A good knowledge of relevant allergens for the individual species is therefore of great importance. Currently, the knowledge about relevant veterinary allergens is based on sensitisation rates identified by intradermal testing or serum testing for allergen-specific IgE; unmodified allergen extracts are the basis for most allergy diagnosis evaluations.

In recent years, increasing research in the field of veterinary allergology has led to the development of novel reagents and technologies, resulting in newly identified clinically relevant allergens and a deeper understanding of animal-specific pathogenesis of allergic diseases. This availability of methodologies for diagnosis and therapy, together with an increasing awareness of allergic diseases in veterinary practice as well as in the general population of companion animal owners, facilitated this development.

In the human field, more and more allergens have been generated by using recombinant DNA technology. Such recombinant allergens are to date primarily used for component-resolved allergy diagnostics in humans. In the veterinary field, these recombinant proteins are used for *in vitro* testing and their potential therapeutic use for AIT/SIT is also under research. It is expected that in the future these could be used for commercial *in vivo* tests and/or AIT/SIT.

With the advance of knowledge on animal allergies and allergens, there is a need to provide an updated guidance on the data requirements for quality, safety and efficacy of conventional and novel allergen products for *in vivo* diagnosis and AIT/SIT.

The European Pharmacopoeia (Ph. Eur.) monograph on allergen products (1063) addresses the technical quality of allergen products that are based on allergen extracts. Although it is recognised that Ph. Eur. monograph 1063 does not necessarily apply to allergen products for veterinary use, it is considered that the manufacturing process is similar, if not the same, for human and veterinary allergens. Thus, the general principles included in this monograph can also be applied to veterinary allergens. Additionally, it is to be taken on board that five monographs on source materials for allergen

products have been elaborated (Ph. Eur. 2621 - Animal epithelia and outgrowths, Ph. Eur. 2623 - Hymenoptera venoms, Ph. Eur. 2625 – Mites, Ph. Eur. 2626 – Moulds and Ph. Eur. 2627 - Pollens).

The previous veterinary allergen Note for Guidance (7BIm11a) included bacterial and parasite allergens (tuberculin, brucellin, toxoplasma, echinococcus, etc.) in its scope. As these agents cause infectious diseases and are now covered by other guidelines and monographs, they are not included in the scope of this guideline. This guideline applies only to allergens that cause allergic diseases.

Another reason to revise the previous Note for Guidance (7BIm11a) is to define and apply (wherever possible) the general concept of "homologous groups" as described in the human allergen guideline "Guideline on Allergen products: Production and quality issues" (EMEA/CHMP/BWP/304831/2007).

Finally, the safety and efficacy sections have been updated in line with the current legislation as previous guidance on clinical aspects was very limited.

# 2. Scope

This document provides principles and guidance on requirements for the manufacturing and quality control, and demonstration of safety and efficacy of veterinary allergen products of biological origin, including allergen extracts from natural source materials and allergens produced through recombinant DNA technology, used for AIT/SIT or *in vivo* diagnosis of IgE-mediated allergic diseases for horses, dogs and cats.

It applies to all veterinary allergen products and their intermediates prepared industrially or by a method involving an industrial process as per article 2(1) of Regulation (EU) 2019/6 of the European Parliament and of the Council.

Allergen products are obtained from allergen extracts, allergoids, conjugates or allergens manufactured using recombinant DNA technology. This guideline does not cover allergenic preparations consisting of synthetic peptides, DNA or RNA constructs and/or cell preparations or low molecular weight chemical allergens.

This document also provides guidance on the establishment and use of in-house reference preparations (IHRP) for quality control including the analysis of batch-to-batch consistency. Moreover, criteria for the preparation of the serum pools used for potency measurements are defined.

Further, this document provides guidance on the design of studies to be performed to demonstrate safety and efficacy of allergen products.

# 3. Legal basis

This guideline has to be read in conjunction with Regulation (EU) 2019/6, Commission Delegated Regulation (EU) 2021/805 amending Annex II of Regulation (EU) 2019/6, Ph. Eur. texts and monographs as well as other relevant EU and VICH guidelines applicable to IVMPs.

The following Ph. Eur. monographs should be considered as relevant: Ph. Eur. monograph 1063 (Allergen products) and specific Ph. Eur. monographs on source materials for allergen products (Ph. Eur. monograph 2621 - Animal epithelia and outgrowths, Ph. Eur. monograph 2623 - Hymenoptera venoms, Ph. Eur. monograph 2625 - Mites, Ph. Eur. monograph 2626 - Moulds and Ph. Eur. monograph 2627 - Pollens).

In accordance with the provisions of the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes and Directive 2010/63/EU on the protection of

animals used for scientific purposes), the 3R principles (replacement, reduction and refinement) should be applied.

# 4. General concepts

## *4.1. Homologous groups*

Due to the high number of allergens in an allergen extract or in an allergen extract mixture and the cross-reactivity of the individual components, it is impossible to determine all relevant parameters for the allergens within a given extract or a defined allergen extract mixture. Therefore, in the previous Note for Guidance on “Specific requirements for the production and control of allergen products (7BIm11a)” extrapolation of stability, safety and efficacy data among members of taxonomic families was defined in a very broad sense.

The concept of homologous groups introduced in the guideline for human allergens (EMEA/CHMP/BWP/304831/2007) replaces the concept of taxonomic families. This new concept limits the extrapolation to groups defined and justified by scientific criteria, restricts extrapolation to a few parameters while, at the same time, it retains the required flexibility.

Allergen extracts prepared from different species, different genera or different families, and finished products which are derived from these allergen extracts and for which clinical experience already exists, may be grouped into homologous groups (for the different animal species in which they are intended to be used).

The grouping of allergens should be based on following criteria:

- For the same animal species (horse, dog or cat);
- Comparable physicochemical and biological properties of the source material;
- Cross-reactivity (within the homologous group)/structural homology of the allergens;
- Identical formulation of the finished product;
- Identical production process of the allergen extract and of the finished product.

All five criteria above must be fulfilled to define a homologous group.

One member of a homologous group is selected as the representative allergen. This choice should be justified, taking into consideration for example geographical differences in the sensitisation patterns and other relevant factors.

To a certain extent data on quality (stability), safety and efficacy can be extrapolated from the representative allergen to other members of the homologous group. For allergens that cannot be included in a homologous group, data for quality, safety and efficacy have to be provided on an individual basis.

Within a homologous group, safety and efficacy studies are only requested for the representative allergen. Post-marketing safety and/or efficacy data could be requested for non-representative allergens of the same homologous group.

Currently, no homologous groups have been defined for horse, dog and cat allergens but some major allergens have been identified. The proposed homologous groups should be specifically justified.

Annex I of this guideline includes a list of allergens of documented importance in horses, dogs and cats and allergens that have been characterised at the molecular level (with bibliographic references).

Proposed homologous groups for human allergens are also listed in Annex II of this guideline to reflect the present knowledge and for reference.

Both, Annexes I and II reflect the current situation and may change over time.

## *4.2. Allergen mixtures*

Allergen extract mixtures should be prepared from individual extracts from single source materials. Therefore, different source materials should not be mixed prior to extraction. Since extracts are considered as active substances (see section 5.1), each individual extract in an allergen mixture should be considered as an active substance on its own. Potency testing should be performed for each individual active substance prior to mixing. Total allergenic activity has to be determined at the finished product level or, if this is not possible, on the first homogeneous mixture. If the testing of the individual active substances in the finished product is not possible due to cross-reactivity of the constituents, the total allergenic activity of the finished product should be determined by a competitive IgE-binding test or by a suitable equivalent *in vitro* method.

The number of allergen extracts in a mixture should be kept to a minimum regardless of homology and cross-reactivity of the individual allergens. The number and the relative proportion of the individual active substances should be justified. If in a mixture the allergens do not belong to the same homologous group, the combination of the components has to be justified.

The following issues should be taken into consideration for allergen extract mixtures and mixtures of recombinant allergens:

- Allergens with proteolytic activities should not be used in mixtures unless justified;
- Perennial and seasonal allergens should not be mixed;
- Hymenoptera venoms should not be mixed with any other allergens. Venoms from different genera should not be mixed.

## *4.3. Comparability (batch-to batch consistency)*

During the development of an allergen product, changes may be introduced in the manufacturing process, which would have an impact on the finished product. Given its complex nature, it is particularly important that all stages of the development process are fully evaluated and all the changes identified within the dossier, where applicable.

Applicants should take into consideration the step-by-step manufacturing approach according to veterinary medicines EU legislation, Ph. Eur. and CVMP/VICH guidance applicable to immunological veterinary medicinal products (IVMP) (for example, Guideline on requirements for the production and control of immunological veterinary medicinal products EMA/CVMP/IWP/206555/2010–Rev.2), considering not only the characterisation studies at the level of the active substance, but also the validation of the manufacturing process as well as in-process controls and stability data.

# 5. Quality

## 5.1. *Active substance*

### 5.1.1. General information

The principles laid down in the section “source materials” of Ph. Eur. monograph 1063 should be applied.

The active substance can be an allergen extract, a purified natural or recombinant protein, all of which can be unmodified or modified (e.g. physically and/or chemically as an allergoid or conjugate).

The active substance should be a stable preparation at the latest step before mixing or formulation of the final product. In general, adsorption and addition of excipients are considered as formulation steps.

Allergen extracts mainly consist of proteins and glycoproteins and contain various major and minor allergens as well as non-allergenic components. Because of the intrinsic variability of the natural source material, concentrations of individual allergens in such extracts may vary and standardisation is therefore very important (for each animal species those are intended for).

Active substances obtained by recombinant DNA technology consist of pre-defined allergenic polypeptides, for example a major allergen, or a mixture of defined polypeptides. The quantity and structure of these polypeptides can be determined and these products should be characterised as defined in Ph. Eur. monographs and the EMA/VICH guidelines relevant for biotechnological products for veterinary use.

### 5.1.2. Manufacture

#### *5.1.2.1. Manufacture of the active substance derived from natural source materials of biological origin*

The principles laid down in the section “source materials” of Ph. Eur. monograph 1063 should be applied.

The production process steps including e.g. pre-treatment, extraction, filtration, dialysis, concentration or freeze-drying should be described in detail and validated. Data can be extrapolated from the representative allergen of the same homologous group, provided that the manufacturing process for the active substance and finished product are identical (see also section 5.3.2). The in-process control methods including the corresponding acceptance criteria should be reported. A flowchart indicating all process steps, including the relevant in-process controls, should be presented. If aseptic precautions are introduced, these should also be indicated in the flowchart. In case of modified allergen extracts such as allergoids or conjugates, the modification processes should be described. Intermediates in the manufacturing process should be identified and controlled.

#### *5.1.2.2. Manufacture of the active substance derived from recombinant DNA technology*

In contrast to allergen preparations obtained from natural source materials of biological origin, the quality of individual allergen batches obtained by recombinant DNA technology does not vary according to the properties and quality of the individual source materials, but depends on the cell systems used, fermentation processes and purification procedures. Therefore, a detailed characterisation of the cell lines used and the manufacturing process is required as described in the relevant guidance documents.

For the production of recombinant allergens, Ph. Eur. monographs relevant for veterinary medicinal products derived from recombinant DNA technology have to be taken into consideration (Ph. Eur.

monograph 0784 – Recombinant DNA technology, products of), and any relevant guidelines (e.g. VICH GL40 Test procedures and acceptance criteria for new biotechnological/biological veterinary medicinal products) could be considered, even if those are not directly applicable for allergenic extracts.

### 5.1.3. Control of starting materials

This section includes starting (source) materials (for example, natural source materials of biological origin for allergen extracts and cell substrates for the production of recombinant proteins) and raw materials (for example, solvents and diluents for extraction, media for the cultivation of mites or moulds and media and reagents for production of recombinant proteins).

When substances of animal or human origin are used as source materials or as raw materials, viral safety (Ph. Eur. chapter 5.1.7) and compliance with TSE requirements (Note for guidance EMA/410/01 rev.3) should be demonstrated to avoid the risk of transmission of infectious diseases. Source materials should be shown to be free from extraneous agents, in line with Ph. Eur. texts (Ph. Eur. 5.2.5) and EU guidelines applicable to IVMPs.

#### *5.1.3.1. Control of source materials for allergen extracts*

The name(s) and address of the supplier(s) of the allergenic source material should be stated. The description of the allergenic source materials should contain all relevant details, as indicated below. The name (scientific name, for example genus and species as well as any common name), and type (e.g. pollen and other plant-derived material, insect venoms, pelt, dander, saliva or foods) of the allergenic source material(s) should be stated. Details concerning the cultivation, collection, pre-treatment (e.g. irradiation steps) and storage should be supplied for each separate source material. Whenever purification steps (for example defatting) or other treatments are performed by the supplier of the source material, these activities have to be mentioned and justified; moreover, acceptance limits have to be defined. The quality control of source materials should be documented. Acceptance criteria and control methods for the source material(s) should be included. They should encompass requirements and control methods relating to identity and purity. The acceptance criteria should ensure the consistency of the allergenic source material from a qualitative and quantitative point of view. The source materials should be stored and transported under controlled conditions justified by stability data. If source materials from different suppliers are mixed to achieve uniform source material batches, the underlying concept should be described and the uniformity of the mixture should be justified.

Each individual source material has to be qualified regardless of whether it belongs to the same homologous group.

Requirements for specific source materials:

*Pollens:* The Ph. Eur. monograph 2627 is considered applicable to veterinary allergens.

*Moulds:* The Ph. Eur. monograph 2626 is considered applicable to veterinary allergens.

Strains which produce mycotoxins such as aflatoxins or ochratoxins should not be used unless justified and, if used, their mutagenic potential should be evaluated. In this case, the amount of relevant mycotoxins should be quantified before processing and their removal through processing should be implemented and validated. Appropriate measures have to be implemented to avoid contamination by other mould strains.

*Mites:* The Ph. Eur. monograph 2625 is considered applicable to veterinary allergens.

*Insects:* Insects such as *Culicoides spp.* for horses and fleas for dogs and cats which are important allergens, do not have specific Ph. Eur. monographs, however for these source materials the principles laid down in the section "source materials" of Ph. Eur. monograph 1063 should be applied.

*Animal epithelia and outgrowths, human epithelia:*

Ph. Eur. monograph 2621 is considered applicable to veterinary allergens. For human epithelia, the principles laid down in the section "source materials" of Ph. Eur. monograph 1063 should be applied.

All substances of human and/or animal origin should be either sterilised or subject to an inactivation procedure by a suitable validated method. These materials should be shown to be free from extraneous agents in line with Ph. Eur. texts, monographs and EU guidelines applicable to IVMPs.

*Hymenoptera venoms:* Ph. Eur. monograph 2623 is considered applicable to veterinary allergens.

*Food allergens:* The principles laid down in the section "source materials" of the Ph. Eur. 1063 should be applied. Food should be of quality for animal consumption.

#### ***5.1.3.2. Control of source materials used for the manufacture of recombinant allergens***

For recombinant allergens, all relevant Ph. Eur. monographs and guidelines indicated above and included in 5.1.2.2 have to be considered.

#### ***5.1.3.3. Control of raw materials***

For each raw material, the specifications, information on its source and justification for its use should be provided.

If any allergenic components are used in the culture medium, their removal in the manufacturing process should be demonstrated.

### 5.1.4. Characterisation and control of the active substance

#### ***5.1.4.1. Characterisation and control of allergen extracts***

The principles laid down in Ph. Eur. monograph 1063 should be followed, with the following specific points for allergens for veterinary use:

IDENTIFICATION (by comparison with in-house reference preparation (IHRP))

TESTS

- Water or loss on drying (if applicable)
- Sterility
- Microbial contamination (non-sterile allergen products)
- Protein content
- Protein profile: that should correspond to that of the IHRP
- Aluminium (when aluminium hydroxide or aluminium phosphate is used as adsorbent)
- Calcium (when calcium phosphate is used as adsorbent)
- Tests on impurities, if considered necessary

- Allergen profile: relevant individual allergens may be determined by immunochemical methods using allergen-specific antibodies derived from the relevant target species.
- Major allergen content for the target species: the allergens relevant for the individual target species may be determined by immunochemical methods using allergen-specific antibodies for the relevant target species.
- Total allergenic activity for the target species: assayed by inhibition of the binding capacity of specific IgE antibodies or by a suitable equivalent in vitro method.
- Individual allergens as indicated in the Ph. Eur. monograph 1063.

The allergens relevant for the product have to be defined by the manufacturer. During the manufacturing process, the presence of the allergens should be confirmed using appropriate methods such as antibody-based techniques or mass spectrometry. The content of relevant allergens should be measured by validated assays using certified reference standards or biological reference preparations and assays validated in international standardisation programmes whenever possible. The protein profile should correspond to that of the IHRP and the presence of the relevant allergen components be verified whenever possible. The choice of the relevant allergen components must be justified. If a significant part of the total allergenic activity or safety concerns arise from other (for example minor) allergens, these have to be measured as well.

The manufacturer should provide batch-to-batch consistency data and provide a justification for the selected and validated test procedures.

#### *5.1.4.2. Characterisation and control of recombinant allergens*

Emphasis should be put on the structural integrity and the consistency of protein folding since these factors may influence the immunogenic properties and safety in AIT/SIT. Investigation of post-translational modifications such as glycosylation should be considered where appropriate. The intact biological function (for example physiological function as plant enzyme) of an allergenic protein derived from recombinant DNA technology may serve as an indirect indicator of structural integrity but is not an essential property determining allergenicity or immuno-modulating activity.

Attention should be given to potential impurities from the media or host cell components. These impurities should be identified and quantified and their potential to give rise to undesirable and potentially allergic reactions should be estimated. If considered necessary appropriate tests on the relevant impurities should be added to routine product testing.

Recombinant allergens should be characterised and quantified by techniques appropriate for recombinant proteins (considering all applicable legislation and guidelines for recombinant IVMPs). The content should be expressed in weight per volume, whenever possible. The correlation between the quantity of the individual recombinant allergens and the corresponding biological (for example allergenic) activity should be shown in validation studies. For recombinant allergen molecules, the potency should be measured by testing inhibition of the binding capacity of specific IgE antibodies or by a suitable equivalent *in vitro* method.

For mixtures of different recombinant allergens, the content of the individual allergens should be determined by adequate quantification methods, for example ELISA just prior to mixing and in the mixture, unless otherwise justified. The general rules given in section 4.1.2 (Allergen mixtures) should be considered, where applicable.

#### *5.1.4.3. Characterisation and control of modified allergen preparations*

For modified allergens (for example denatured or chemically-modified allergoids or conjugates), antibody-based assays or other appropriate test methods have to be established to identify the relevant allergens in the modified form. Other assays should be used to analyse and characterise the expected modification of the allergens. The consistency of the modification process should be demonstrated, for example by peptide mapping or mass spectrometry. To determine the degree of polymerisation, size-exclusion chromatography could be performed and further suitable parameters could be analysed (e.g. presence of amine groups).

#### *5.1.4.4. Potency assays*

As stated in Ph. Eur. monograph 1063, the potency assay should be performed as late as possible in the manufacturing process, preferably on the finished product. If justified, potency control can be performed on the active substance and /or at the intermediate stage between the active substance and the finished product prior to mixing single allergens.

Total allergenic activity for the target species should be measured by testing inhibition of the binding capacity of specific IgE antibodies from a sera pool (c.f. standard & reference materials) or by a suitable equivalent *in vitro* method.

For allergoids, potency tests should consist of a discriminatory test or a combination of immunological tests to distinguish between native and modified molecules (e.g. by quantification in ELISA systems or mediator release assay), and an assay to determine the lack of IgE reactivity. As an alternative to a discriminatory immunoassay, other techniques (e.g. mass spectrometry) may be used to demonstrate the presence of the relevant allergens.

For conjugates, the potency testing should consider the immuno-modulating properties of the specific modifications.

### 5.1.5. Stability of the active substance

For all allergens, if the active substance is stored, stability data should be obtained according to the relevant guidelines on stability testing (EMA/CVMP/IWP/206555/2010-Rev.2) to support the maximum storage period. The general principles defined in VICH GL 17 (CVMP/VICH/501/99-FINAL) guideline for biological/biotechnological products should also be considered for allergen extracts.

Regarding homologous groups, full stability data should be presented for the representative allergen of each homologous group. For the non-representative allergens within a homologous group, stability studies may be performed on an ongoing basis for the shelf life of the active substance. If these data are not available at the time of submission of a marketing authorisation application, the data may need to be provided post-authorisation. The marketing authorisation application should contain a detailed protocol of the stability studies of the non-representative allergens. If justified, some stability data may be extrapolated from the representative allergen. The extrapolation of the results from the representative allergen should be discussed and justified, taking into account data concerning the activity of those enzymes (such as proteases) which might impact on the structure of the individual molecules.

## *5.2. Standards and reference materials*

Reference standard materials should be established and characterised for all types of allergen products and for each target species.

In-house reference preparations (IHRP) for allergen extracts:

Follow the guidance in Ph. Eur. monograph 1063, considering the following:

The extent of characterisation of the IHRP depends on the source material, knowledge of the allergenic components and availability of suitable reagents, as well as the intended use including target animal species. The proposed and characterised IHRP is used as the reference in the batch control of active substances and intermediates and if possible in the batch control of finished product.

The biological potency of the first IHRP is determined in the target species (by *in vivo* method such as skin reactivity and/or by an *in vitro* suitable method). Subsequently the biological activity of the future IHRPs is determined by *in vitro* methods by comparison with the results in the first IHRP.

In-house reference preparations for recombinant proteins:

For the IHRP used for the quality control of recombinant allergens, in general the criteria defined in VICH GL17 guideline should be followed and potency testing according to section 5.1.4.2 should be applied. Justification for the reference material as well as the testing strategy chosen should be provided.

Sera pools:

A sera pool could be established for batch control and for the qualification of individual IHRP. The problem of geographically different sensitisation patterns should be taken into consideration in the preparation of the pools. For the used sera, the frequency of IgE-recognition of different allergens as well as the content of allergen-specific IgE antibodies and the clinical relevance of sensitisation should be taken into account when preparing the pool. The pool should be composed of sera from at least 10 animals of the target species, unless justified. Sera recognising carbohydrate epitopes and sera from animals that had a previous AIT/SIT treatment with the respective or cross-reactive allergen should not be included in the pool. In addition, sera containing IgE antibodies against bovine serum albumin, milk proteins or gelatine should be avoided in the pool unless otherwise justified. Specifications should be set for the sera pool, including criteria for the reactivity profile of the pool. Prior to use, quality of the pooled sera should be demonstrated by appropriate control experiments. This should include the demonstration that the relevant allergens are recognised by the pools.

## *5.3. Manufacturing and control of finished product*

### 5.3.1. Description and composition of the finished product

A detailed description of the finished product should be given. If the finished product consists of a mixture of active substances, a complete list of all the active substances used should be given. In general, adsorption and addition of excipients are regarded as formulation, and these steps should be described in the manufacturing process of the finished product.

### 5.3.2. Manufacture

The manufacturing process should be described in detail, including process scale. A step-by-step diagram (flowchart) should be presented, indicating all process steps and including the relevant in-process controls. If aseptic precautions are introduced, these should also be described and indicated in the flowchart. Process holding times should be identified and justified. Description, documentation and results of the validation of the manufacturing process should be provided. If justified, a reduced validation program can be applied for the non-representative allergen products of the same homologous group provided that the manufacturing process is identical to that of the representative

allergen product and for which full validation data should be available. For the non-representative allergens, the critical steps and key parameters should be identified and integrated in the reduced validation program.

If further adsorption or modification steps are performed, these manufacturing steps have to be described in detail and reported in the flowchart. The purpose of these steps should be explained. In addition, tests should be carried out to demonstrate the success of these activities and the consistency of production.

### 5.3.3. Control of the finished product

Appropriate specifications should be set for the finished product, in line with Ph. Eur. monograph 1063. As stated in the monograph, control tests should be performed as late as possible in the manufacturing process. If justified, defined control tests can be performed on the active substance and/or at the intermediate stage between the active substance and the finished product prior to mixing single allergens.

The characteristics of the finished product should be documented for all strengths (dilutions). Where appropriate testing is not possible due to methodological limitations, this should be justified. Guidance provided in previous parts of this guideline that are also relevant to the control of the finished product should be taken into account.

Appropriate tests are as follows and as indicated in point 5.1.4.1.:

Identification (by comparison with IHRP), water, sterility, microbial contamination, protein content, protein profile, aluminium, calcium, allergen profile, impurities (if relevant), total allergenic activity, individual allergens.

Control of non-modified allergen preparations

Total allergenic activity determined by a competitive IgE-binding test is absolutely required for the standardisation and batch control of finished products containing non-modified allergens. Consequently, the labelling should include an indication of the strength in potency units.
If test systems validated in international standardisation programmes are available for the quantification of individual allergens*,* these should be applied. In that case, the content in weight per volume of the individual allergens should be included in the specifications of the finished product and should be indicated in the Summary of Product Characteristics (SPC) in addition to potency.
If safety concerns arise from individual minor allergens, these have to be measured as well.

Control of allergen mixtures

For allergen mixtures, potency testing should be performed for each individual allergen active substance in the mixture. If the testing of the individual active substances in the finished product is not possible due to cross-reactivity of the constituents, the total potency of the finished product should be determined by a competitive IgE-binding test or by a suitable equivalent *in vitro* method.

Control of adsorbed products

For adsorbed products, the efficacy and stability of the adsorption has to be determined by measuring the amount of total soluble protein and/or the presence of IgE-binding components in the supernatant or by using other relevant methods at least at release and at the end of the shelf life period. These parameters should be followed during the stability studies performed for adsorbed products.

Control of recombinant allergens

Finished products containing recombinant allergens have to comply with the Ph. Eur. monograph 0784 "Products of recombinant DNA technology", and also the VICH GL40 "Test procedures and acceptance criteria for new biotechnological/biological veterinary medicinal products" could be considered even if not directly applicable for allergenic extracts.

The content of the purified protein (for example major allergen) and the potency, as described in chapters 5.1.4.2 and 5.1.4.4, should be determined.

### 5.3.4. Container closure system

The container closure system(s) used should be described in detail. Additionally, all other parts of the final veterinary medicinal product including for example solvents for reconstitution or medical device and/or device part used/supplied for application of the product have to be described.

### 5.3.5. Stability of the finished product

Stability testing should be performed as real-time stability studies as indicated in the relevant guidance documents (e.g. EMA/CVMP/IWP/206555/2010 where applicable), using stability-indicating assays (including potency). Sterility testing (Ph. Eur. chapter 2.6.1) should be performed for all parenteral preparations, eye preparations, preparations for inhalation or preparations intended for skin prick testing. If preservatives are used e.g. in multi-use containers, the efficacy of the antimicrobial preservation should be tested according to the relevant Ph. Eur. chapter (5.1.3. Efficacy of Antimicrobial Preservation). Products not required to be sterile (e.g. for oral route) have to comply with the requirements defined in the Ph. Eur. chapter 5.1.4. (Microbiological Quality of Pharmaceutical Preparations).

For allergen extracts belonging to the same homologous group, a full set of stability data has to be provided for the representative allergen. For the non-representative allergens some stability data may be extrapolated from the 'representative' allergen. Therefore, only a limited number of parameters may be tested in these studies. The choice of these parameters should be justified.

The extrapolation of the results from the representative allergen should be discussed and justified. Extrapolation may not be possible for all allergen products, e.g. differences of enzymatic activities between the representative and the non-representative allergens have to be considered if relevant for the stability of the product. The data for the non-representative allergens may be obtained in ongoing real-time stability studies after granting of a marketing authorisation. If the data are not available at the time of submission of a marketing authorisation, a commitment should be made to continue the stability studies after approval. The marketing authorisation application should contain a detailed protocol of the stability studies of the non-representative allergens.

If the finished product consists of a mixture of allergen extracts not belonging to the same homologous group, stability studies have to be performed for the mixture considering each individual active substance. If the individual extracts in a mixture belong to the same homologous group and therefore cross-reactivity occurs between the relevant allergens, it may not be possible to determine the activity of the individual active substances. In such cases (for example a mixture of grass pollen extracts), an overall potency determined by a competitive IgE-binding test may be appropriate. The selected testing strategy should be described in detail and justified.

For allergen extracts, stability studies of finished products manufactured with active substance at the end of its shelf life should be performed. The study should be initiated once during development or a commitment should be given to initiate such a study after marketing approval.

For adsorbed products, the stability of the adsorption and/or modification has to be proven at the end of the shelf life by testing the total amount of soluble protein in the supernatant and/or by determining the presence of IgE-binding components in the supernatant or by using other relevant methods. In order to prove the stability of products containing native and modified allergens, mediator release assays (e.g. with mouse IgE and rat basophil leukaemia cells) may be considered as potency tests.

If it is not possible to perform potency tests, for example in case of adsorbed material, *in vivo* immunogenicity tests or validated alternative *in vitro* tests should be performed in the stability studies at the beginning and end of the proposed shelf-life period. The stability study should be initiated during development, to provide evidence on the stability of the finished product.

# 6. Safety and Efficacy testing

The mode of action of allergen immunotherapy (AIT/SIT) is not fully understood in humans, nor in the three animal species which are the subject of this guideline. Therefore, only the minimum requirements for safety and efficacy studies to be performed with allergens for veterinary use are described.

For safety and efficacy testing of IVMPs, Annex II of Regulation EU 2019/6 and Ph. Eur. chapters 5.2.6 and 5.2.7 require pre-clinical studies on the final product in each category of each target animal species, by each recommended administration route. Pre-clinical studies according to these requirements may not be possible for allergen immunotherapy (AIT/SIT) due to the unique nature of allergic diseases in sensitised animals. Furthermore, GLP safety studies in unsensitised animals have little relevance for the safety profile of the AIT/SIT in the target group of sensitised animals and in the interests of the 3Rs such studies should only be conducted if there are specific concerns related to the use of the AIT/SIT in non-allergic animals.

As for human allergen products, no pharmacokinetic / pharmacodynamic studies are required for veterinary allergens. This is also in line with the classification of these products as immunologicals. Pharmacokinetic studies are not possible for products of allergen immunotherapy, since plasma concentrations of the active substance during the therapy are usually not measurable due to the nature of the product.

To show the effect of AIT/SIT on the immune system, immunological changes (e.g. changes in allergen specific IgG levels, T-cell responses, and/or cytokine production) and/or modifications of the end organ (e.g. respiratory tract, skin) specific response (e.g. provocation tests) should be measured. These evaluations can be included in safety and efficacy studies. Dedicated pharmacodynamic studies are not requested.

Clinical (field) trials are considered the most appropriate means of demonstrating the safety and efficacy of AIT/SITs as the complexity of studying allergic diseases in sensitised animals cannot be replicated easily under laboratory conditions.

Clinical trials using sensitised animals should be appropriately designed and conducted with representative product batches. Consideration should be given to the minimum and maximum number of allergens and the approach justified, the target animals and categories and recommended routes of administration, and dosing schedule.

The concept of homologous groups can be adopted for the evaluation of safety and efficacy.

Data obtained on one member of the group (representative allergen) may be extrapolated to another member of that group provided that all the criteria for grouping of allergens described in 4.1 are met. In the case of mixtures of members of different homologous groups, extrapolation from one group to the other is not acceptable.

## *6.1. Safety studies with veterinary allergen products for immunotherapy treatment*

Depending on the nature and variability of final products, safety data obtained from single allergen extracts if adequately justified, could be also acceptable to demonstrate the safety of the final product, provided that adjuvants and/or other immunostimulants included in the final product are also contained in the studies evaluating safety of the "single allergen extracts".

Safety profile data derived from use of the allergen products in sensitised animals are expected to be more informative than safety data gained in unsensitised animals. Thus, results/data from target animal clinical trials, from validated experimental models and, if available, from pharmacovigilance reports are considered suitable when assessing target animal safety. As such, it is of high relevance to investigate the safety profile of these products in detail in the pivotal clinical trials in naturally sensitised animals.

Any experimental model of sensitisation needs to be appropriately validated, and its biological relevance to be justified for the extrapolation of the results to spontaneous allergic disease.

If pre-clinical studies in sensitised animals are possible, the safety and efficacy may be demonstrated in the same pre-clinical study. Standard batches may be used with no requirement to demonstrate the safety with batches formulated with maximum allergen content, but maximum allergen content should be justified.

Overdose safety studies for AIT/SIT products are not required.

As outlined above, due to the unique nature of allergic diseases, it is recommended to investigate the safety of veterinary allergens in clinical trials carried out in naturally sensitised animals. The efficacy of the product could also be demonstrated in the same clinical trial. Standard batches may be used but minimum and maximum allergen content should be justified.

Consideration should be given to the target animals and categories in these studies. It may be required to include a specifically sensitive category in the safety studies or provide appropriate published data to this extent. Alternatively, the specific exclusion of certain sensitive categories may be required.

The safety parameters to be evaluated include but are not limited to:

Possible adverse reactions such as local reactions (injection site, for injectables) and systemic reactions (e.g. lethargy, vomiting, diarrhoea, pruritus, anaphylaxis, enlargement of lymph nodes).

Expected allergic side effects should be distinguished into immediate or delayed effects according to the time of appearance (immediate when the onset of the reaction is during the first 30 minutes after administration and delayed when the onset is later than 30 minutes after administration) and into local and systemic effects according to the site of the appearance of the reaction (local when the reaction takes place at the administration site and systemic when the reaction takes place at a site other than the administration site).

Safety of repeated administration, following the AIT/SIT protocol recommendation, should be performed for each target species and by each recommended route. Studies for the examination of reproductive performance and immunological functions may be omitted. If such studies are not performed, relevant warnings should be included in the SPC.

The use of documentation based on scientific publications to suitably support safety of the allergen treatment product is acceptable, provided the data is relevant/appropriate.

## *6.2. Efficacy studies with veterinary allergen products for immunotherapy treatment*

Taking into consideration the manufacturing process of these products, efficacy of allergen treatments could be shown for each allergen extract alone and/ or in the final product.

If the final formulation contains adjuvants and/or other immunostimulants, efficacy studies should be performed including these components.

In the studies performed to demonstrate efficacy, as clinical response to AIT/SIT is allergen specific, animals to be included in these studies should be carefully selected based on the clinical allergy history, results of intradermal testing, allergen specific serum IgE testing, or results of any other suitable allergy diagnostic test, if justified.

Efficacy studies should include control non-treated/placebo animals.

The efficacy of each allergen extract should be demonstrated by each recommended route of administration unless scientific data can be provided demonstrating that extrapolation from one recommended route to another is possible.

From the data available to date, the target animal category (e.g. age, breeds with special predispositions) used for the demonstration of efficacy of allergens appears in general not to be a crucial point. Nevertheless, efficacy should be evaluated in animals representative of the target population and the test population should be described in detail.

Possible known negative impacts on the efficacy induced by certain allergen extracts mixed in the same final product should be taken into account. This evaluation could be based on published scientific data.

Efficacy could be also demonstrated under laboratory conditions in animals naturally or experimentally sensitised to the allergen of interest. In principle, efficacy could be demonstrated by a challenge/provocation test under laboratory conditions (e.g. common practice in AIT/SIT dose-finding studies in humans). Any experimental sensitisation model needs to be appropriately validated, and its biological relevance justified as relates to extrapolating the results to spontaneous allergic disease.

Safety and efficacy may be demonstrated in the same pre-clinical study or clinical trial. Standard batches may be used with no requirement to demonstrate the efficacy with batches formulated with minimum allergen content, but minimum allergen content should be justified.

As outlined above due to the unique nature of allergic diseases it is recommended to investigate the efficacy of allergens in clinical trials carried out in naturally sensitised animals.

<u>Data to be recorded:</u> success rates could be evaluated by complete remission, and/or improvement of clinical signs and/or reduction of concomitant medication.

Clinical signs that could be measured in dogs: lesions scores, pruritus scores for atopy, medication scores.

Clinical signs that could be measured in cats: lesions scores, pruritus scores for feline eosinophilic granuloma complex, milliary dermatitis, self-inflicted alopecia, pruritus, seborrhoea.

Clinical signs that could be measured in horses: lesions scores, pruritus scores for atopy, urticaria and recurrent airway obstruction.

Further surrogate parameters for efficacy might be acceptable if a correlation can be demonstrated between the specific parameters and protection induced by the treatment. A follow-up of these

surrogate parameters might be considered sufficient to substantiate the efficacy claim (Examples for Antibody response: increase in IgG, decrease in IgE, etc.; Examples for Cellular immune response: increase in IFN gamma, IL-10; decrease in IL-4 or others, as indicated in the publication Lowestein and Mueller, 2009).

Time to observe the efficacy of the AIT/SIT: Any time period chosen should be justified.

Interaction with other medicinal treatment: The possible interaction with other treatments (e.g. antihistamines, glucocorticoids, cyclosporine, janus kinase inhibitors, other immunological veterinary medicinal products and/or monoclonal antibodies) should be considered (either evaluated in the context of clinical studies or by reference to the published literature) and indicated in the product information.

The use of documentation based on scientific publications to demonstrate the efficacy of therapeutic allergens, is acceptable, provided the studies provided are relevant to the product under evaluation, the target animal species and are appropriately designed and described in detail.

## *6.3. Safety and Efficacy studies for in vivo diagnosis with veterinary allergen products*

To demonstrate the safety and efficacy of these products, the final formulation, the route of administration, target concentration and the different animal species should be considered.

The safety data that would be acceptable are in general the same as for immunotherapy products (for each separate allergen).

To demonstrate the efficacy of diagnosis, the specificity and sensitivity of the testing procedure should be demonstrated, with the dose indicated and the period of observation proposed for each target species.

Taking into account the different formulation and in general different administration routes between therapy and *in vivo* diagnosis products, safety and efficacy studies already performed for AIT/SIT allergens from the same manufacturer, could be appropriate to demonstrate safety and could be supportive for the efficacy of the same allergens used for *in vivo* diagnosis (skin test allergen).

# Definitions

An allergen is a molecule capable of inducing an IgE response and/or a Type I allergic reaction.

Recombinant allergens are proteins obtained by recombinant DNA technology. The coding sequence may represent the complete sequence of individual allergens or only parts of it. Recombinant allergens may have an allergenic activity comparable to the natural allergen but the preparations may also have low IgE-binding capacity due to the selection of natural hypoallergenic variants or induced by sequence alterations or physico-chemical modifications.

Allergen extracts are extracts from natural biological source materials containing a mixture of allergenic and non-allergenic molecules.

Veterinary allergen products are veterinary medicinal products containing allergens or derivatives of allergens for the purpose of *in vivo* diagnosis or treatment of allergic diseases.

Major/minor allergens are allergens, against which at least 50% (major allergens) or less than 50% (minor allergens) of the patients tested have allergen-specific immunoglobulin E (IgE) antibodies.

Relevant allergens are allergens causing a clinically relevant effect in a significant proportion of the allergic patients.

Allergoids are allergens, which are chemically modified to reduce IgE reactivity.

Conjugates are allergens, which are covalently coupled to other molecules to modulate their immunological properties.

Immunotherapy treatment (AIT: Allergen Immunotherapy treatment/ SIT: Specific Immunotherapy treatment: an allergen/ specific treatment of allergic diseases in animals, reducing the degree of sensitisation using allergen extracts.

Allergen mixtures: Mixtures of allergen extracts. These should be prepared from individual extracts from single source materials.

Homologous groups: Allergen extracts prepared from different species, different genera or different families and finished products derived from these allergen extracts may be grouped in homologous groups based on the composition and the physico-chemical as well as biological properties of the source material, the cross-reactivity/structural homology of allergens, the formulation of the finished product and the production process of the allergen extract and of the finished product.

Representative/ non-representative allergens in a homologous group: Each homologous group is represented by one or more allergens based on scientific information about the allergens and their cross-reactivity with other members of the same homologous group. Data may be extrapolated from these representative allergens to other allergens of the same homologous group. These other allergens of the same homologous group are referred to as non-representative allergens.

Total allergenic activity is defined as the capacity to bind specific IgE antibodies from allergic subjects measured by a competitive IgE-binding test.

A competitive IgE-binding test is used to determine the total allergenic activity. The assays involved comprise for example IgE-inhibition assays with animal IgE being inhibited from binding to reference allergens in the solid phase by the allergen sample (dilution series) in the liquid phase, as well as assays with a constant amount of labelled allergens and the allergen sample (dilution series) competing for specific binding to IgE-antibodies bound to a solid phase.

The potency is the "quantitative measure of the biological activity based on the attribute of the product which is linked to the relevant biological properties", using a suitable quantitative biological assay (also called potency assay or bioassay). For unmodified allergens or allergen extracts, total allergenic activity may serve as indicator of potency.

# References

Fischer, N.M., Müller, R.S. Allergen Specific Immunotherapy in Canine Atopic Dermatitis: an Update. Curr Derm Rep 8, 297–302 (2019). https://doi.org/10.1007/s13671-019-00276-z

Foj R, Carrasco I, Clemente F, Scarampella F, Calvet A, Prats A, Vivancos S, Brazís P, Puigdemont A. Clinical efficacy of sublingual allergen-specific immunotherapy in 22 cats with atopic dermatitis. Vet Dermatol. 2021 Feb;32(1):67-e12.

Ginel PJ, Hernández E, Lucena R, Blanco B, Novales M, Mozos E. Allergen-specific immunotherapy in horses with insect bite hypersensitivity: a double-blind, randomized, placebo-controlled study. Vet Dermatol. 2014 Feb;25(1):29.

Halliwell R, Banovic F, Mueller RS, Olivry T. Immunopathogenesis of the feline atopic syndrome. Vet Dermatol. 2021; 32: 13– e4.

Halliwell R, Pucheu-Haston CM, Olivry T, Prost C, Jackson H, Banovic F, et al. Feline allergic diseases: introduction and proposed nomenclature. Vet Dermatol. 2021; 32: 8– e2.

Hobi S, Mueller RS. Efficacy and safety of rush immunotherapy with alum-precipitated allergens in canine atopic dermatitis. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2014;42(3):167-73.

Lee-Fowler TM, Cohn LA, DeClue AE, Spinka CM, Reinero CR. Evaluation of subcutaneous versus mucosal (intranasal) allergen-specific rush immunotherapy in experimental feline asthma. Vet Immunol Immunopathol. 2009 May 15;129(1-2):49-56.

Lee-Fowler TM, Cohn LA, DeClue AE, Spinka CM, Ellebracht RD, Reinero CR. Comparison of intradermal skin testing (IDST) and serum allergen-specific IgE determination in an experimental model of feline asthma. Vet Immunol Immunopathol. 2009 Nov 15;132(1):46-52.

Lee SP, Shin YS, Kang SY, Kim TB, Lee SM. Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review. Immune Netw. 2022 Feb 7;22(1):e12. doi: 10.4110/in.2022.22.e12. PMID: 35291653; PMCID: PMC8901700.

Loewenstein C, Mueller RS. A review of allergen-specific immunotherapy in human and veterinary medicine. Vet Dermatol. 2009 Apr;20(2):84-98.

Lorenz AR, Lüttkopf D, May S, Scheurer S, Vieths S. The principle of homologous groups in regulatory affairs of allergen products--a proposal. Int Arch Allergy Immunol. 2009;148(1):1-17.

Marsella R. Advances in our understanding of canine atopic dermatitis. Vet Dermatol. 2021 Dec;32(6):547-e151. doi: 10.1111/vde.12965. Epub 2021 Apr 23. PMID: 33891338.

Mueller RS, Janda J, Jensen-Jarolim E, Rhyner C, Marti E. Allergens in veterinary medicine. Allergy. 2016 Jan;71(1):27-35.

Mueller R.S and Bettenay S.V. Long-term Immunotherapy of 146 Dogs with Atopic Dermatitis – a Retrospective Study (1996). Aust. Vet. Practit. 26(3):128.

Mueller R.S and Bettenay S.V. Evaluation of the safety of an abbreviated course of injections of allergen extracts (rush immunotherapy) for the treatment of dogs with atopic dermatitis. 2001. Am J Vet Res. 2001 Mar;62(3):307-10.

Mueller R.S., K.V.Fieseler, S. Zabel, R.A.W. Rosychuk. Conventional and rush immunotherapy in canine atopic dermatitis. 2004. Vet dermatology. Volume 15, Issue s1 Page 4.

Mueller RS, Jensen-Jarolim E, Roth-Walter F, Marti E, Janda J, Seida AA, DeBoer D. Allergen immunotherapy in people, dogs, cats and horses - differences, similarities and research needs. Allergy. 2018 Oct;73(10):1989-1999.

Mueller RS. Update on Allergen Immunotherapy. Vet Clin North Am Small Anim Pract. 2019 Jan;49(1):1-7. doi: 10.1016/j.cvsm.2018.08.001. Epub 2018 Sep 15. PMID: 30227970.

Mueller RS, Nuttall T, Prost C, Schulz B, Bizikova P. Treatment of the feline atopic syndrome - a systematic review. Vet Dermatol. 2021 Feb;32(1):43-e8. doi: 10.1111/vde.12933. PMID: 33470011.

Mueller RS. A systematic review of allergen immunotherapy, a successful therapy for canine atopic dermatitis and feline atopic skin syndrome. J Am Vet Med Assoc. 2023 Mar 24:1-6. doi: 10.2460/javma.22.12.0576. Epub ahead of print. PMID: 36940185.

Nelson HS. Standardized allergen extracts for allergen immunotherapy. Allergy Asthma Proc. 2022 Jul 1;43(4):327-332. doi: 10.2500/aap.2022.43.220015. PMID: 35818139.

Reinero CR, Byerly JR, Berghaus RD, Berghaus LJ, Schelegle ES, Hyde DM, Gershwin LJ Rush immunotherapy in an experimental model of feline allergic asthma. Vet Immunol Immunopathol 2006;110(1-2):141-153.

Reinero CR, et al. Immunomodulation with allergen-specific immunotherapy in feline asthma. Invited expanded research abstract, Veterinary Comparative Respiratory Society, ACVIM Forum, 2009.

Schnabl B., Bettenay S.V., Dow K, Mueller R.S.. Results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis. Vet Rec. 2006 Jan 21;158(3):81-5.

Stepnik CT, Outerbridge CA, White SD, Kass PH. Equine atopic skin disease and response to allergen-specific immunotherapy: a retrospective study at the University of California-Davis (1991-2008). Vet Dermatol. 2012 Feb;23(1):29-35, e7.

Trimmer AM, Griffin CE, Boord MJ, Rosenkrantz WS. Rush allergen specific immunotherapy protocol in feline atopic dermatitis: a pilot study of four cats. Vet Dermatol. 2005 Oct;16(5):324-9.

Trimmer AM, Griffin CE, Rosenkrantz WS. Feline immunotherapy. Clin Tech Small Anim Pract. 2006 Aug;21(3):157-61.

Vidémont E. and Pin D. How to treat atopy in cats? EJCAP – 2009 December. Vol. 19 - Issue 3: 276-282.

White SD. Approach to the pruritic horse. J Am Vet Med Assoc. 2023 Jan 19:1-9. doi: 10.2460/javma.22.10.0444. Epub ahead of print. PMID: 36638000.

Yu A.A. Treatment of Equine Allergies. AAEP RESORT SYMPOSIUM / 2015.

# ANNEX I

**Allergens with documented importance (Horses/Dogs/Cats)**

***Summary from Mueller et al. ,*** Allergy 2016 (71: 27-35).

**Horses:**

**Mites:** Reported, but no clear conclusions

**Insects:** *Culicoides spp.*

**Plant derived:** (tree, grass and weed pollens).

**Mould:** *Aspergillus fumigatus, Alternaria alternata and Penicillium notatum*

**Dogs:**

**Mites:** *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*

Less frequent: *Acarus siro*, *Lepidoglyphus destructor* and *Tyrophagus putrescentiae*

**Plant derived:** (tree, grass and weed pollens)

The most important is *Cryoptomeria japonica* pollen (CryJ3 is a major allergen in dogs)

**Insects:** Flea (Major allergen in dogs is Ctef1 of *Ctenocephalides felis* and other very minor)

**Moulds**: Not known

**Cats:**

**Mites:** *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*

**Plant derived:** (pollens).

**Insects:** Flea, and also hymenoptera and mosquito

**Moulds**: Not known

**Allergens of documented importance in domestic animals that have been characterised at the molecular level. (*Mueller et al 2016):***

| Allergen source | Allergen name | Identity/ homology MW(kDa) | Relevant in species |
|---|---|---|---|
| **Mites:** | | | |
| *Dermatophygoides farinae* | Der f 15 | Chitinase 98/109 | Dog |
| | Der f 18 | Chitinase 60 | Dog |
| **Pollen:** | | | |
| *Cryptomeria japonica* | Cry j 1 | Pectate lyase 41 | Human/ Dog |
| *Cryptomeria japonica* | Cry j 2 | Polygalacturonase 56 | Human/ Dog |
| *Cryptomeria japonica* | Cry j 3 | Thaumatin-like protein 24 | Human/ Dog |
| **Insects:** | | | |
| *Ctenocephalides felis* | Cte f 1 | None 18 | Dog |
| *Culicoides nubeculosus* | Cul n 1 | Antigen-5 like 25 | Horse |
| | Cul n 2 | Hyaluronidase 46.7 | Horse |
| | Cul n 3 | Cysteine endopeptidase 44.6 | Horse |
| | Cul n 4 | None 17.5 | Horse |
| | Cul n 5 | None 45.7 | Horse |
| | Cul n 6 | None 16.9 | Horse |

| | | | |
|---|---|---|---|
| | Cul n 7 | None 20.9 | Horse |
| | Cul n 8 | Maltase 68.7 | Horse |
| | Cul n 9 | D7-related 15.5 | Horse |
| | Cul n 10 | None 47.8 | Horse |
| | Cul n 11 | Trypsin 30.1 | Horse |
| *Culicoides obsoletus* | Cul o 1* | Maltase 66.8 | Horse |
| | Cul o 2* | Hyaluronidase 42.3 | Horse |
| | Cul o 3 | Antigen-5 like 27.9 | Horse |
| | Cul o 4 | Trypsin 27.1 | Horse |
| | Cul o 5 | None 17.9 | Horse |
| | Cul o 6 | D7-related 15.2 | Horse |
| | Cul o 7 | None 15 | Horse |
| | Cul o 1* | Kunitz protease inhibitor 23.3 | Horse |
| | Cul o 2* | D7-related 17.5 | Horse |
| *Culicoides sonorensis* | Cul s 1 | Maltase 66 | Horse |
| *Simulium vittatum* | Sim v 1 | Antigen 5 like 29.8 | Horse |
| | Sim v 2 | Kunitz protease Inhibitor 9.6 | Horse |
| | Sim v 3 | A-amylase 28 | Horse |
| | Sim v 4 | a-amylase 26 | Horse |
| **Moulds:** | | | |
| *Aspergillus fumigatus* | Asp f 7 | None 27.4 | Human/ horse |
| | Asp f 8 | Acidic P 2 ribosomal proteins 11 | Human/ horse |

*Nomenclature needs modification. These allergen sequences were submitted to GenBank at the same time by different groups.

# ANNEX II

**Proposed homologous groups- Human allergens [Lorenz 2008]**

One member of a homologous group is selected as the representative species. This choice should be justified, taking into consideration for example geographical differences in the sensitisation patterns and other relevant factors.

## 1. Tree pollen

The 'birch group' or 'fagales group'

*Betula verrucosa = B. pendula* = B. alba* European white birch
*Alnus glutinosa* Alder
*Carpinus betulus* Hornbeam
*Corylus avellana* Hazel
*Quercus alba* Oak
*Castanea sativa* Sweet chestnut
*Fagus sylvatica* Beech
* Correct taxonomic name according to NCBI taxonomic database

The group of Oleaceae

*Olea europaea* Olive
*Fraxinus excelsior* Ash
*Ligustrum vulgare* Privet
*Syringa vulgaris* Lilac

The group of Cupressaceae

*Juniperus* sp. Cedar
*Cupressus* sp. Cypress

## 2. Grass and cereal pollen

The group of sweet grasses of the *Poaceae* (*Gramineae*) family, subfamily of *Pooideae*

Non-grouped species within tree pollen species. Justification required.

*Fagus sylvatica* European beech
*Acer* sp. Maple
*Platanus* sp. Plane tree
*Populus* sp. Poplar
*Robinia pseudoacacia* False acacia, Locust tree
*Salix* sp. Sallow / Willow
*Tilia* sp. Linden / Lime tree
*Ulmus* sp. Elm
*Cryptomeria japonica* Japanese Cedar
*Anthoxanthum odoratum* Sweet vernal grass
*Avena sativa* Oat
*Dactylis glomerata* Orchard grass/Cocksfoot *Festuca* sp.
Meadow fescue
*Holcus lanatus* Velvet grass/Yorkshire fog
*Hordeum vulgare* Barley

*Lolium perenne* Perennial ryegrass
*Phleum pratense* Timothy grass
*Poa pratensis* Kentucky bluegrass
*Secale cereale* Cultivated rye *Triticum aestivum*
Cultivated wheat

Additional grass species belonging to the homologous group of Pooideae with reservations:

*Agropyron* sp. Couch grass, Crested wheatgrass
*Agrostis* sp. Bent grass
*Alopecurus pratensis* Meadow foxtail
*Arrhenatherum elatius* False oat
*Bromus* sp. Brome grass

Non-grouped grass pollen species. Justification required.

*Cynodon dactylon* Bermuda grass
*Cynosurus cristatus* Dogstail

## 3. Weed pollen

The group of weed pollen species

*Ambrosia artemisiifolia*, *Ambrosia trifida* Ragweed
*Artemisia vulgaris* Mugwort
*Parietaria judaica*, *Parietaria officinalis* Pellitory

Non-grouped weed species. Justification required.

*Plantago* sp. Plantain

## 4. Mites

The group of house dust mites of the *Dermatophagoides* genus

*Dermatophagoides pteronyssinus*
*Dermatophagoides farina*

Non-grouped mite species. Justification required.

*Acarus siro* flour mite
*Glycyphagus domesticus* house mite
*Lepidoglyphus destructor* house mite
*Thyreophagus entomophagus* flour mite
*Tyrophagus putrescentiae* storage mite

## 5. Insect venoms

No homologous groups formed. Justification required.

## 6. Allergen extracts derived from vertebrates

Extracts such as animal epithelia, hair, dander.

No homologous group formed. Non-grouped species. Justification required.

*Canis familiaris* Dog
*Felis domesticus* Cat
*Cavia porcellus* Guinea pig
*Cricetus* Hamster *Equus*
*caballus* Horse
*Mus musculus* Mouse
*Oryctolagus cuniculus* Rabbit
*Rattus* sp. Rat

## 7. Moulds

No homologous group formed. Justification required; in case of justification of grouping of mould species, special emphasis on similar stability is necessary.